# Editorial: Regulators of the immune-tumor microenvironment: a new frontier for cancer immunotherapy

**Authors:** Reem A. Assal, Rana A. Youness, Mai F. Ragab, Noha M. Elemam

PMC · DOI: 10.3389/fmed.2026.1764720 · Frontiers in Medicine · 2026-02-09

## Full-text entities

- **Genes:** CD226 (CD226 molecule) [NCBI Gene 10666] {aka DNAM-1, DNAM1, PTA1, TLiSA1}, HLA-E (major histocompatibility complex, class I, E) [NCBI Gene 3133] {aka HLA-6.2, QA1}, CRTAP (cartilage associated protein) [NCBI Gene 10491] {aka CASP, LEPREL3, OI7, P3H5}, P3H1 (prolyl 3-hydroxylase 1) [NCBI Gene 64175] {aka GROS1, LEPRE1, OI8}, P3H4 (prolyl 3-hydroxylase family member 4 (inactive)) [NCBI Gene 10609] {aka LEPREL4, NO55, NOL55, SC65}, P3H2 (prolyl 3-hydroxylase 2) [NCBI Gene 55214] {aka LEPREL1, MCVD, MLAT4}, CD38 (CD38 molecule) [NCBI Gene 952] {aka ADPRC 1, ADPRC1, cADPR1}, PVR (PVR cell adhesion molecule) [NCBI Gene 5817] {aka CD155, HVED, NECL5, Necl-5, PVS, TAGE4}, VDR (vitamin D receptor) [NCBI Gene 7421] {aka NR1I1, PPP1R163}, CD276 (CD276 molecule) [NCBI Gene 80381] {aka 4Ig-B7-H3, B7-H3, B7H3, B7RP-2}, TNFRSF17 (TNF receptor superfamily member 17) [NCBI Gene 608] {aka BCM, BCMA, CD269, TNFRSF13A}, NT5E (5'-nucleotidase ecto) [NCBI Gene 4907] {aka CALJA, CD73, E5NT, NT, NT5, NTE}, MIF (macrophage migration inhibitory factor) [NCBI Gene 4282] {aka GIF, GLIF, MMIF}, Tgm2 (transglutaminase 2, C polypeptide) [NCBI Gene 21817] {aka G[a]h, TG2, TGase2, tTG, tTGas}, P3H3 (prolyl 3-hydroxylase 3) [NCBI Gene 10536] {aka GRCB, HSU47926, LEPREL2}, CGAS (cyclic GMP-AMP synthase) [NCBI Gene 115004] {aka C6orf150, D4, MB21D1, h-cGAS}, NECTIN2 (nectin cell adhesion molecule 2) [NCBI Gene 5819] {aka CD112, HVEB, PRR2, PVRL2, PVRR2}, AFP (alpha fetoprotein) [NCBI Gene 174] {aka AFPD, FETA, HPAFP}, GPRC5D (G protein-coupled receptor class C group 5 member D) [NCBI Gene 55507], VHL (von Hippel-Lindau tumor suppressor) [NCBI Gene 7428] {aka HRCA1, RCA1, VHL1, pVHL}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}
- **Diseases:** NSCLC (MESH:D002289), hypoxia (MESH:D000860), hematologic tumors (MESH:D019337), myelodysplastic syndromes (MESH:D009190), tumorigenesis (MESH:D063646), EMPD (MESH:D010145), ESCC (MESH:D000077277), Lung cancer (MESH:D008175), neurotoxicity (MESH:D020258), MM (MESH:D009101), Aggressive cancers (MESH:D009369), sleep disorder (MESH:D012893), inflammation (MESH:D007249), HCC (MESH:D006528), Ovarian cancer (MESH:D010051), sleep fragmentation (MESH:D012892), OSA (MESH:D020181), cytokine release syndrome (MESH:D000080424), B cell lymphomas (MESH:D016393), triple-negative breast cancer (MESH:D064726), breast cancer (MESH:D001943), gynecological malignancy (MESH:D005833), colorectal cancer (MESH:D015179), metastasis (MESH:D009362)
- **Chemicals:** N6-methyladenosine (MESH:C010223), docetaxel (MESH:D000077143), m6A (MESH:C005955), Sudocetaxel (-)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12926139/full.md

---
Source: https://tomesphere.com/paper/PMC12926139